Brokerages Set Colgate-Palmolive (NYSE:CL) Price Target at $84.75

Shares of Colgate-Palmolive (NYSE:CL – Get Rating) have earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $84.75.

A number of brokerages have commented on CL. Morgan Stanley raised shares of Colgate-Palmolive from an “equal weight” rating to an “overweight” rating and set a $82.00 price objective for the company in a research note on Monday, January 30th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Colgate-Palmolive from $80.00 to $88.00 in a research note on Monday, May 1st. Citigroup lifted their price objective on shares of Colgate-Palmolive from $88.00 to $92.00 in a research note on Monday, May 1st. UBS Group raised their target price on shares of Colgate-Palmolive from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, March 29th. Finally, Barclays lowered their target price on shares of Colgate-Palmolive from $80.00 to $77.00 and set an “equal weight” rating for the company in a report on Tuesday, January 31st.

Insider Activity at Colgate-Palmolive

In other news, Director John P. Bilbrey sold 5,703 shares of the business’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $80.81, for a total value of $460,859.43. Following the completion of the sale, the director now owns 26,257 shares in the company, valued at approximately $2,121,828.17. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Sally Massey sold 17,239 shares of the business’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $81.16, for a total value of $1,399,117.24. Following the completion of the sale, the insider now owns 8,615 shares in the company, valued at approximately $699,193.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John P. Bilbrey sold 5,703 shares of Colgate-Palmolive stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $80.81, for a total transaction of $460,859.43. Following the completion of the transaction, the director now directly owns 26,257 shares in the company, valued at approximately $2,121,828.17. The disclosure for this sale can be found here. Insiders sold 187,748 shares of company stock worth $15,138,660 in the last 90 days. 0.34% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CL. Beaumont Financial Advisors LLC increased its position in Colgate-Palmolive by 2.7% during the 1st quarter. Beaumont Financial Advisors LLC now owns 4,842 shares of the company’s stock worth $364,000 after purchasing an additional 127 shares in the last quarter. NorthRock Partners LLC increased its position in Colgate-Palmolive by 4.7% during the 1st quarter. NorthRock Partners LLC now owns 2,824 shares of the company’s stock worth $212,000 after purchasing an additional 128 shares in the last quarter. Equitable Holdings Inc. increased its position in Colgate-Palmolive by 1.7% during the 3rd quarter. Equitable Holdings Inc. now owns 7,780 shares of the company’s stock worth $547,000 after purchasing an additional 133 shares in the last quarter. Rowland & Co. Investment Counsel ADV increased its position in Colgate-Palmolive by 3.7% during the 1st quarter. Rowland & Co. Investment Counsel ADV now owns 3,695 shares of the company’s stock worth $278,000 after purchasing an additional 133 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC grew its position in Colgate-Palmolive by 2.1% in the first quarter. Gladstone Institutional Advisory LLC now owns 6,329 shares of the company’s stock valued at $476,000 after acquiring an additional 133 shares in the last quarter. Hedge funds and other institutional investors own 77.63% of the company’s stock.

Colgate-Palmolive Stock Performance

CL opened at $76.25 on Tuesday. The stock has a market capitalization of $63.25 billion, a price-to-earnings ratio of 39.71, a PEG ratio of 3.95 and a beta of 0.49. The company has a fifty day moving average of $77.10 and a 200 day moving average of $76.22. Colgate-Palmolive has a fifty-two week low of $67.84 and a fifty-two week high of $83.81. The company has a debt-to-equity ratio of 20.87, a quick ratio of 0.76 and a current ratio of 1.23.

Colgate-Palmolive (NYSE:CL – Get Rating) last posted its earnings results on Friday, April 28th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.03. Colgate-Palmolive had a net margin of 8.71% and a return on equity of 348.63%. The company had revenue of $4.77 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period last year, the company posted $0.74 earnings per share. Colgate-Palmolive’s quarterly revenue was up 8.4% on a year-over-year basis. As a group, sell-side analysts forecast that Colgate-Palmolive will post 3.14 earnings per share for the current fiscal year.

Colgate-Palmolive Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 15th. Investors of record on Friday, April 21st were issued a dividend of $0.48 per share. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.47. The ex-dividend date of this dividend was Thursday, April 20th. This represents a $1.92 dividend on an annualized basis and a yield of 2.52%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 100.00%.

Colgate-Palmolive Company Profile

(Get Rating)

Colgate-Palmolive Co is engaged in the manufacturing and distribution of consumer products. It operates through the Oral, Personal and Home Care, and Pet Nutrition segments. The Oral, Personal and Home Care segment represents North America, Latin America, Europe, Asia Pacific, and Africa or Eurasia, all of which sell to a variety of retail and wholesale customers and distributors.